Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of BMS-707035 in HIV-1 Infected Subjects
NCT00397566Phase 2Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2007
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in human immunodeficiency virus type 1 infection (HIV-1) comparing BMS-707035 with Placebo (2 arms). Primary endpoint: Antiviral activity of selected doses of BMS-707035 at 10 days. Planned start Feb 2007; status: withdrawn.
02
Drugs
BMS-707035
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00397566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00397566.